ImmunityBio, Inc. Announces Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression In Advanced Head-And-Neck Cancer Patients
Portfolio Pulse from Happy Mohamed
ImmunityBio, Inc. (NASDAQ:IBRX) announced findings from a Phase 1 study indicating that allogeneic cytokine-induced memory-like (CIML) natural killer (NK) cells used in combination with ImmunityBio's IL-15 superagonist N-803 may induce tumor regression in advanced head-and-neck cancer patients. The study, sponsored by Dana-Farber Cancer Institute, showed that tumor regression was associated with expansion of the NK cell type with cytolytic activity. The results may have potential implications for many of the estimated 68,000 men and women in the United States who are diagnosed with head-and-neck cancers annually.
July 10, 2023 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunityBio's Phase 1 study results indicate potential for a new treatment approach for advanced head-and-neck cancer patients. This could have a positive impact on the company's stock as it shows progress in their research and development efforts.
The positive results from ImmunityBio's Phase 1 study indicate potential for a new treatment approach for advanced head-and-neck cancer patients. This could lead to increased investor confidence in the company's research and development capabilities, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100